Alto Neuroscience posts Phase 2a ALTO-207 depression trial data showing MADRS improvement

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00
  • Alto Neuroscience presented Phase 2a trial results for depression drug candidate ALTO-207 at 2026 Society of Biological Psychiatry annual meeting.
  • Study showed meaningful improvement in depressive symptoms versus placebo, supporting further development of fixed-dose pramipexole-ondansetron combination.
  • Trial results indicated patients were able to reach higher pramipexole doses more quickly, addressing tolerability issues that have limited use of pramipexole in routine care.
  • No maintenance-phase discontinuations tied to adverse events were reported in ALTO-207 arm, with nausea remaining an observed side effect.
  • Company advanced ALTO-207 into Phase 2b trial in treatment-resistant depression, with updated titration schedule aimed at improving tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260504596889) on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.